BiomX develops phage cocktails (or combinations) that target and kill specific pathogenic bacteria. Our phage cocktails, which are optimized through algorithms and experimental validation (in-vitro and in-vivo), contain multiple natural and/or engineered phage. The phage are selected to have complementary functions such as wide target bacterial host range and the ability to avoid the development of bacterial resistance, among other characteristics.
A. Bacteriophage Background
Bacteriophage, or phage, are viruses that target bacteria and are considered inert to mammalian cells. Phage are natural predators of bacteria and are found wherever bacteria exist. Phage are specific to particular bacterial species or strains, targeting and killing them without disrupting other neighboring, potentially beneficial, bacteria.
B. Phage Therapy
The BOLT Platform and our Development Process
The BOLT platform (“BacteriOphage Lead to Treatment”) is comprised of proprietary computational tools, automated screening, synthetic engineering capabilities and various validation assays aimed at developing natural or engineered phage cocktails that target a particular pathogenic bacteria. We apply the platform to develop phage cocktails directed through two development paths as outlined below.
Personalized Phage Treatment
Tailored to target strains of a specific patient within 6-8 weeks. Running such production suites in parallel for multiple patients allows to conduct a clinical Personalized proof of concept within 12-18 months from project initiation.
Optimized Phage Therapy
Optimized for bacterial host range, resistance, other factors, to target a broad patient population as a go to market product. Usually requires 1-2 years to develop.
C. Biomarker Discovery
The bacteria present in our gut have shown promise as a predictive tool for the existence and staging of medical conditions such as IBD, liver disease, colorectal cancer and cardiovascular diseases. Recent publications have also demonstrated the potential to predict response to specific therapeutics for IBD and immuno-oncology based on bacterial gut composition. Our first-of-its-kind XMarker platform uses a unique metagenomics-based approach to discover predictive microbial genomic signatures that can be further developed into biomarkers. The platform combines ultra-high-resolution DNA analysis, AI techniques and high-scale cloud computing resources to build classifiers of high sensitivity and specificity.
Sign up for the latest updatesJoin our mailing list to receive company updates
delivered to your inbox Join the list